CD8A and myasthenia gravis: Ben-David et al. showed that in an experimental model of MG where pathology is triggered by immunization with a myasthenogenic peptide, injection of a dual-altered peptide induces the emergence of CD8+CD28− Treg that efficiently suppress the autoimmune response.